Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
TTNP > SEC Filings for TTNP > Form 8-K on 4-Sep-2013All Recent SEC Filings

Show all filings for TITAN PHARMACEUTICALS INC

Form 8-K for TITAN PHARMACEUTICALS INC


4-Sep-2013

Other Events, Financial Statements and Exhibits


Item 8.01. Other Events.

FDA Meeting Request

On September 4, 2013, Titan Pharmaceuticals, Inc. (the "Company" or "Titan") announced that a request for a meeting has been submitted to the U.S. Food and Drug Administration ("FDA") to discuss Probuphine.

The press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

Braeburn Management

Braeburn Pharmaceuticals Sprl ("Braeburn") has advised the Company that Frank Young, M.D., Ph.D. has joined Braeburn as Executive Vice President, Clinical and Regulatory Affairs, and will assume Garry Neil, M.D.'s role as Braeburn's representative in connection with all oral and written communications with the FDA relating to the Probuphine New Drug Application. Dr. Young served as Commissioner of the FDA between 1984 and 1989.



Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press release dated September 4, 2013.


  Add TTNP to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for TTNP - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.